Department of Neurology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Mult Scler. 2018 May;24(6):696-700. doi: 10.1177/1352458518768770. Epub 2018 Apr 9.
While there is now a multitude of potent medications for relapsing-remitting multiple sclerosis (RRMS), effective therapies targeting neurodegeneration in progressive multiple sclerosis types are still lacking. Stimulation of neurorepair in this disease remains a pathogenetically defined treatment goal. However, therapeutic progress is slowed by the still inadequate tool set to capture "regeneration/repair" in MS and to define appropriate outcomes in clinical trials.
In this review, we discuss studies investigating promising regenerative agents for progressive MS which were recently presented during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)/Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 meeting in Paris.
虽然目前有许多治疗复发缓解型多发性硬化症（RRMS）的有效药物，但针对进展型多发性硬化症类型的神经退行性变的有效治疗方法仍缺乏。在这种疾病中刺激神经修复仍然是一个具有明确病理的治疗目标。然而，治疗进展仍然受到限制，因为目前还没有足够的工具来捕捉多发性硬化症中的“再生/修复”，也无法在临床试验中定义适当的结果。
在本次综述中，我们讨论了在最近于 2017 年巴黎举行的欧洲多发性硬化症治疗和研究委员会（ECTRIMS）/美洲多发性硬化症治疗和研究委员会（ACTRIMS）会议上提出的用于治疗进展型多发性硬化症的有前途的再生药物的研究。
